Rezolute, Inc. (RZLT)

3.1200 -0.0700 (-2.19%) At close: 04:00PM EDT

Rezolute, Inc.

201 Redwood Shores Parkway
Suite 315
Redwood City, CA 94065
United States
650 206 4507
https://www.rezolutebio.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 26

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Nevan Charles Elam J.D.	Founder, CEO & Director	1.01M	N/A	1967
Dr. Brian Kenneth Roberts M.D.	Chief Medical Officer	744.74k	N/A	1975
Mr. Chris Milks	VP & Head of Fin.	N/A	N/A	N/A
Mr. Michael R. Deperro	Sr. VP & Head of Technical Operations	N/A	N/A	N/A
Dr. Davelyn Eaves Hood M.B.A., M.D.	Director and Head of Scientific & Patient Affairs	N/A	N/A	N/A
Mr. Michael Covarrubias	VP & Head of CMC	N/A	N/A	N/A
Dr. Raj Agrawal M.D.	VP & Head of Ophthalmological Clinical Devel.	N/A	N/A	N/A
Ms. Robyn Sweinhart	VP & Head of Quality	N/A	N/A	N/A
Ms. Erin O'Boyle	VP & Head of Clinical Operations	N/A	N/A	N/A

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Corporate Governance

Rezolute, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.